Issues

Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Based on the FDA-approved antibody pertuzumab, we have created a panel of bispecific FynomAbs that target two epitopes on HER2. Confocal laser scanning microscopy performed with HER2-positive NCI-N87 cells showed that bispecific FynomAb COVA208 was able—in contrast to pertuzumab and trastuzumab—to relocalize to the intracellular area after five hours of incubation, appearing in a punctate pattern typically seen for internalized drugs. For details, see article by Brack and colleagues on page 2030.